Back to top
As Canada faces rising cancer rates, mounting system pressures, and growing interest in personalized care, new national modelling provides timely insight into the costs and benefits of expanding access to comprehensive genomic profiling—helping leaders make informed decisions in a rapidly evolving landscape.
Comprehensive genomic profiling (CGP) can deliver faster, more precise diagnoses—enabling patients to access therapies that better match their tumour biology.
This new modelling shows that publicly funding CGP for five high-burden de novo metastatic cancers could result in potential healthcare system savings of $87M - $134M, add approximately 3,440 life-years across the patient population, and generate over $180 million in societal value, over a 6-year horizon, from 2025-2030. Yet despite its proven value, access to CGP remains fragmented across Canada, underscoring the need for coordinated, national action.
Download the full reports below.
Precision in Practice: Costs and Benefits of Comprehensive Genomic Profiling for Five Stage 4 Cancers (Full Report)
La précision en pratique : coûts et avantages du profilage génomique complet pour cinq cancers de stade 4 (Rapport complet)
Advancing Cancer Care in Canada: Unlocking Better Outcomes and Smarter Spending Through Genomic Profiling (Summary for Executives)
Faire progresser les soins contre le cancer au Canada : De meilleurs résultats et des dépenses plus judicieuses grâce au profilage génomique (Résumé à l’intention des dirigeants)
.png){kind=logo}
